Role of fixed combinations in the management of open-angle glaucoma

References

• Resnikoff S, Pascolini D, Etya’ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ.82(11), 844–851 (2004).
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. In: Terminology and Guidelines for Glaucoma, 3rd Edition. Editrice Dogma, Savona, Italy (2008).
   Google Scholar
• Gordon MO, Beiser JA, Brandt JD et al.; The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol.120(6), 714–720 (2002).
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol.121(1), 48–56 (2003).
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE. Canadian Glaucoma Study: risk factors for the progression of open-angle glaucoma. Arch. Ophthalmol.126(8), 1030–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120(10), 1268–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120(6), 701–713 (2002).
   PubMed Web of Science ®Google Scholar
• Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging25(9), 729–759 (2008).
   PubMed Web of Science ®Google Scholar
• Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J. Glaucoma18(3), 238–243 (2009).
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology112(6), 953–961 (2005).
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging24(12), 1007–1016 (2007).
   PubMed Web of Science ®Google Scholar
• Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci.63(3), 333–338 (1974).
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol.4, 1–9 (2010).
   PubMedGoogle Scholar
• Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br. J. Ophthalmol.92(6), 729–734 (2008).
   PubMed Web of Science ®Google Scholar
• Scharrer A, Ober M. [Metipranolol 0.1% and pilocarpine 2% as a fixed combination compared with each substance alone in the treatment of glaucoma. A controlled, randomized clinical study comparing the intraindividual effects and tolerance]. Klin. Monbl. Augenheilkd.189(6), 450–455 (1986).
   PubMed Web of Science ®Google Scholar
• Bron AM, Garcher CP, Sirbat D, Allaire CM, Lablache-Combier MJ, Trinquand CJ. Comparison of two fixed β-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. Eur. J. Ophthalmol.7(4), 351–356 (1997).
   PubMedGoogle Scholar
• Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and tolerance of β-blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J. Glaucoma4(4), 235–241 (1995).
   PubMedGoogle Scholar
• Puustjarvi TJ, Repo LP. Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo Study Group. Arch. Ophthalmol.110(12), 1725–1729 (1992).
   PubMedGoogle Scholar
• Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Trans. Am. Ophthalmol. Soc.94, 89–101 (1996).
   PubMedGoogle Scholar
• Podos SM, Camras CB, Serle JB. Experimental compounds to lower intraocular pressure. Aust. NZ J. Ophthalmol.17(2), 129–135 (1989).
   PubMedGoogle Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol.53(Suppl. 1), S107–S120 (2008).
   PubMed Web of Science ®Google Scholar
• Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr. Pharm. Des.14(7), 649–654 (2008).
   PubMed Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an α2-adrenergic agonist, after four years of continuous use. Expert Opin. Pharmacother.1(4), 815–834 (2000).
   PubMedGoogle Scholar
• Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch. Ophthalmol.123(7), 898–902 (2005).
   PubMed Web of Science ®Google Scholar
• Konstas AG, Tsironi S, Vakalis AN et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol.87(1), 71–76 (2009).
   PubMed Web of Science ®Google Scholar
• Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr. Opin. Ophthalmol.20(2), 79–83 (2009).
   PubMed Web of Science ®Google Scholar
• Konstas AG, Hollo G, Mikropoulos D et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br. J. Ophthalmol.94(2), 209–213 (2010).
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology113(1), 70–76 (2006).
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br. J. Ophthalmol.88(2), 199–203 (2004).
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos D, Kaltsos K, Jenkins JN, Stewart WC. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology113(3), 446–450 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J. Ocul. Pharmacol. Ther.18(5), 401–409 (2002).
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg.26(3), 233–236 (1995).
   PubMedGoogle Scholar
• Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv. Ther.24(2), 376–386 (2007).
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr. Med. Res. Opin.25(10), 2543–2547 (2009).
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Primary Open-angle Glaucoma, Preferred Practice Pattern. American Academy of Ophthalmology, San Francisco, CA, USA (2005).
   Google Scholar
• Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Bimatoprost/timolol fixed combination: a 3 month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma.17(3), 211–216 (2008).
   PubMed Web of Science ®Google Scholar
• Hommer A. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0. 03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur. J. Ophthalmol.17(1), 53–62 (2007).
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12 month randomized trial. Arch. Ophthalmol.124(9), 1230–1238 (2006).
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide–timolol combination versus the concomitant administration of its components. Dorzolamide–Timolol Study Group. Ophthalmology105(10), 1936–1944 (1998).
   PubMed Web of Science ®Google Scholar
• Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br. J. Ophthalmol.82(11), 1249–1253 (1998).
   PubMed Web of Science ®Google Scholar
• Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur. J. Ophthalmol.15(5), 581–590 (2005).
   PubMed Web of Science ®Google Scholar
• Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr. Med. Res. Opin.24(10), 2725–2728 (2008).
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol.140(1), 1–7 (2005).
   PubMed Web of Science ®Google Scholar
• Hommer A, Thygesen J, Ferreras A et al. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. Eur. J. Ophthalmol.18(5), 778–786 (2008).
   PubMed Web of Science ®Google Scholar
• van der Valk V, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology112(7), 1177–1185 (2005).
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol.135(5), 688–703 (2003).
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J. Glaucoma17(8), 667–673 (2008).
   PubMed Web of Science ®Google Scholar
• Holmstrom S, Buchholz P, Walt J, Wickstrom J, Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin.21(11), 1875–1883 (2005).
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Vetrugno M et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur. J. Ophthalmol.19(1), 66–71 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr. Med. Res. Opin.23(5), 1025–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye23(4), 810–818 (2009).
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Gandolfi S et al. Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am. J. Ophthalmol.150(4), 575–580 (2010).
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer HV et al. A 1 year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur. J. Ophthalmol.17(2), 183–190 (2007).
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Jeanbat V, Laurendeau C, Berdeaux G. Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin. Drug Investig.28(12), 767–776 (2008).
   PubMed Web of Science ®Google Scholar
• Yan DB, Gill N. Evaluation of 24-hour post-dose efficacy of travoprost-timolol and latanoprost-timolol fixed combinations in patients with open-angle glaucoma. Presented at: ARVO 2010. Fort Lauderdale, FL, USA, 2–6 May 2010 (Abstract 163/A386).
   Google Scholar
• Rossi GC, Pasinetti GM, Bracchino M et al. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6 month, multicenter, cohort study. Expert Opin. Pharmacother.10(11), 1705–1711 (2009).
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr. Eye Res.33(2), 163–168 (2008).
   PubMed Web of Science ®Google Scholar
• Teus MA, Miglior S, Laganovska G et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthalmol.3, 629–636 (2009).
   PubMedGoogle Scholar
• Manni G, Denis P, Chew P et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma18(4), 293–300 (2009).
   PubMed Web of Science ®Google Scholar
• Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr. Med. Res. Opin.25(7), 1645–1653 (2009).
   PubMed Web of Science ®Google Scholar
• Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, Sa Filho WF. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr. Med. Res. Opin.23(4), 683–689 (2007).
   PubMed Web of Science ®Google Scholar
• Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R Jr. An eight-week, multicentric, randomized, interventional, open-label, Phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J. Glaucoma17(8), 674–679 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Saenz-Frances F, Martinez-de-la-Casa JM et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr. Med. Res. Opin.26(7), 1599–1606 (2010).
   PubMed Web of Science ®Google Scholar
• Ahmed IIK. Combigan early experience data trial (CEED II): an in-depth look at the latest findings. Clin. Surg. J. Ophthalmol.25(2), 50–54 (2007).
   Google Scholar
• Mundorf TK, Rauchman SH, Williams RD, Notivol R; Brinzolamide/timolol preference study group. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthal.2(3), 623–628 (2008).
   PubMedGoogle Scholar
• Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared with BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther.24(6), 601–605 (2008).
   PubMed Web of Science ®Google Scholar
• Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol.130(4), 429–440 (2000).
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol.126(4), 487–497 (1998).
   PubMed Web of Science ®Google Scholar
• Traverso CE, Walt JG, Kelly SP et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br. J. Ophthalmol.89(10), 1245–1249 (2005).
   PubMed Web of Science ®Google Scholar
• Lindblom B, Nordmann JP, Sellem E et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol.Scand.84(1), 74–83 (2006).
   Web of Science ®Google Scholar
• Lee PP, Walt JG, Doyle JJ et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch. Ophthalmol.124(1), 12–19 (2006).
   PubMed Web of Science ®Google Scholar
• Thygesen J, Aagren M, Arnavielle S et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr. Med. Res. Opin.24(6), 1763–1770 (2008).
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics25(4), 287–308 (2007).
   PubMed Web of Science ®Google Scholar
• Traverso CE, Walt JG, Kelly SP et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br. J. Ophthalmol.89(10), 1245–1249 (2005).
   PubMed Web of Science ®Google Scholar
• Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in Medicare beneficiaries with glaucoma. Arch. Ophthalmol.126(6), 849–856 (2008).
   PubMed Web of Science ®Google Scholar
• Ström O. Medical costs of glaucoma in Sweden. Presented at: International Society For Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Ontario, Canada, 3–7 May 2008.
   Google Scholar
• Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J. Glaucoma14(6), 463–469 (2005).
   PubMed Web of Science ®Google Scholar
• Tuil E, Hommer AB, Poulsen PB et al. The cost–effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients – a European perspective. Int. J. Clin. Pract.59(9), 1011–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Hommer A, Buchholz P, Wickstrom J, Walt J. Cost–effectiveness of the fixed combinations brimonidine/timolol and dorzolamide/timolol in 12 countries. Presented at: 106th Deutsche Ophthalmologische Gesellschaft. Berlin, Germany, 18–21 September 2008.
   Google Scholar
• Hommer A, Wickstrom J, Friis MM et al. A cost–effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr. Med. Res. Opin.24(4), 1057–1063 (2008).
   PubMed Web of Science ®Google Scholar